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are higher after NMT while TRM is higher after HDT; and 4)
long term remissions suggest that NMT is associated with an
important graft vs lymphoma effect.
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STABLE LONG TERM ENGRAFTMENT AND AMELIORATION OF CLINICAL
PHENOTYPE FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLAN-
TATION FROM A MATCHED SIBLING DONOR FOR SICKLE CELL DISEASE
USING A REDUCED INTENSITY CONDITIONING REGIMEN
Krishnamurti, L.1; Wu, C.2; Baker, S.3; Yeager, A.M.4; Wagner, J.E.3
1. Children’s Hospital of Pittsburgh, Pittsburgh, PA; 2. Dana Farber
Cancer Institute, Boston, MD; 3. University of Minnesota, Minneapolis,
MN; 4. University of Pittsburgh Medical Center, Pittsburgh, PA.
Hematopoietic stem cell transplantation (HCT) from sibling
donors has been demonstrated to cure hemoglobinopathies such as
sickle cell disease (SCD) and Thalassemia. Concerns about high
regimen related toxicity (RRT) have prevented the use of HCT in
older patients, those with advanced organ damage or those without
a HLA matched related donor. Also, potential for late sequelae
such as chronic graft-versus-host disease (GVHD) and infertility
have limited the acceptance of this treatment even by eligible
patients. HCT following a reduced intensity conditioning (RIC)
regimen has the potential for reducing toxicity and potentially
making this curative therapy more acceptable and applicable to this
group of patients. We initiated a pilot study to evaluate the safety
and efﬁcacy of HCT following a RIC regimen for patients with
high risk hemoglobinopathies. We report stable long term engraft-
ment with amelioration of clinical phenotype in the ﬁrst three
patients with SCD receiving HCT (unmodiﬁed bone marrow)
from a matched sibling donor, on this study. The conditioning
regimen consisted of Busulfan 2 mg/kg orally q 12 hr 2 days (0.8
mg/kg IV q 6 hr  2 days for patient #3), Fludarabine 35 mg/m2/
dose IV daily  5 days, antithymocyte globulin 30 mg/kg/dose IV
daily  5 days and total lymphoid irradiation administered as a
single fraction of 500 cGy with shielding of the liver, lungs, heart,
and gonads. Prophylaxis for GVHD consisted of cyclosporine A
and Mycophenolate mofetil. Clinical characteristics of the patients
and outcomes are summarized in Table 1. The preparative regi-
men was well tolerated with no serious infections or mucositis in
any patient. Nadir of absolute neutrophil count was 140–200 
109/L. Nadir of platelet count was 25–40  109/L. Transfusion
requirements were modest (3 PRBC and 3–5 platelet transfusions).
All patients are off immunosuppressive medications. Recovery of
splenic function was observed except in patient #2 had who had
prior splenectomy. No patient has had any recurrence of previous
sickle cell related symptoms such as stroke, pain crisis, priapism or
acute chest syndrome. End-organ changes are stable in all patients.
Lineage-speciﬁc chimerism analysis (patient #3) suggest predomi-
nance of donor erythropoiesis. These ﬁndings indicate that HCT
for sickle cell disease following a RIC regimen is well tolerated and
can lead to stable long term engraftment with amelioration of
clinical phenotype and stabilization of end- organ damage.
Clinical Characteristics of Patients With Sickle Cell Disease
Undergoing HCT From a Matched Sibling Donor Following a
Reduced Intensity Conditioning Regimen
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INTRAVENOUS BUSULFAN DOSED FOUR TIMES DAILY OR ONCE DAILY
AS PART OF THE STANDARD BUCY PREPARATIVE REGIMEN FOR AL-
LOGENEIC STEM CELL TRANSPLANTATION
Shaughnessy, P.J.; Bachier, C.; Alexander, L.; Bowen, B.; LeMaistre,
C.F. Texas Transplant Institute, San Antonio, TX.
Intravenous busulfan (IVBu) (Busulfex ESP Pharma) is now
regularly substituted for oral busulfan as part of the standard
busulfan and cyclophosphamide (BuCy) preparative regimen for
allogeneic stem cell transplantation (ASCT). Oral busulfan was
originally dosed 4 times daily, which led to the current accepted
dosing schedule for IVBu. Pharmacokinetics (PK) and busulfan
clearance allow for once daily dosing now that IVBu is available.
We performed a retrospective review of 36 consecutive patients
who received the BuCy preparative regimen with IVBu prior to
ASCT. Twenty-one males and 15 females with a median age of 46
years (23–64) were treated for AML (n15), ALL (n1), CML
(n8), MDS (n8), NHL (n2), and multiple myeloma (n2).
IVBu was dosed 0.8 mg/kg 4 times daily for 16 doses (n16) or 3.2
mg/kg once daily for 4 doses (n20) on days 7 to 4, and
cyclophosphamide was dosed 60 mg/kg once daily for two doses on
days 3 and 2. IVBu was dosed by ideal or adjusted ideal body
weight and no PK studies were done. Bone marrow (n6) or
peripheral blood (n30) stem cells were infused on day 0 from
HLA matched siblings (n26) or unrelated donors (n9), and one
partially matched unrelated donor. Engraftment occurred in 34
patients (pts) (94%). Two pts who failed to engraft had bone
marrow grafts with low numbers of total mononuclear cells in-
fused. Regimen related toxicity (RRT) included mild VOD in 2 pts
(5%) that self resolved, with one pt receiving IVBu 4 times daily
and the other once daily. There was no seizure activity or non-
infectious interstitial pneumonitis attributed to RRT in any pa-
tient. Other RRT were not signiﬁcantly different between the
patients who received 4 times daily or once daily IVBu. Day 100
mortality was 17%, and at a median follow up of 12 months (1–54)
17 pts (47%) survive. Five of 16 pts (31%) survive who received 4
times daily IVBu, and 12 of 20 pts (60%) survive who received once
daily IVBu, however, most patients who received once daily IVBu
were treated more recently. Three patients received once daily
IVBu as outpatients. In conclusion, this small retrospective single
institution study revealed IVBu dosed once daily by ideal or ad-
justed ideal body weight appeared to have similar RRT, engraft-
ment, and survival compared to 4 times daily IVBu when used as
part of the BuCy preparative regimen for ASCT.
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HIGH RELAPSE RATE FOLLOWING ALEMTUZAMAB USE IN ALLOGENEIC
TRANSPLANTS FOR MYELOID HEMATOLOGIC MALIGNANCIES
Shea, T.C.1; Serody, J.1; Gabriel, D.1; Comeauu, T.1; Morris, D.2;
Irons, R.1; Harvey, D.3; Sharf, A.1; Krasnov, C.1; Dunphy, C.4; Ban-
derenko, N.4; Brecher, M.4 1. Department of Medicine, Bone Marrow
and Stem Cell Transplant Program; 2. Department of Radiation On-
cology; 3. Department of Pharmacy; 4. Department of Pathology and
Laboratory Medicine, UNC Hospitals, Lineberger Comprehensive Can-
cer Center and School of Medicine, Chapel Hill, NC.
Chakravarti (Blood, ‘02, p 1071) and others have described the
use of alemtuzamab in vivo for control of graft vs host disease in
allotransplantation. Control of GVHD has been good, but high
relapse rates and infectious complications have been reported. We
describe 47 pts, 16 women and 31 men, median age 49, and median
f/u 11 months who underwent matched related (31) or unrelated
(16) bone marrow (8), blood stem cell (38), or both (1), transplants
for hematologic malignancies. All AML pts had high-risk disease
deﬁned as beyond CR1 (11), CR1 with high risk cytogenetics (5),
AML with dysplasia (12), or failed prior autolograft (1). Three had
10% marrow blasts at time of transplant. All other pts had
multiply recurrent disease. All pts received Alemtuzamab at 20
mg/d  5 (17), 30 mg/d  3 (25) or lower doses (5) between days
8 through 4, followed by tacrolimus. Conditioning regimens
included 12.8 mg/kg IV busulfan, (27), 6.4 mg/kg IV busulfan (9),
melphalan 140 mg/m2 (6), or Cy/TBI (1). All non-TBI patients
received 30 mg/m2/d  5 of ﬂudarabine. Median recovery of ANC
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